| Targeting the estrogen receptor for the treatment of breast cancer: recent advances and challenges RK Rej, JE Thomas, RK Acharyya, JM Rae, S Wang Journal of Medicinal Chemistry 66 (13), 8339-8381, 2023 | 19 | 2023 |
| Asymmetric total synthesis of naturally occurring spirocyclic tetranorsesquiterpenoid lanceolactone A RK Acharyya, S Nanda Organic & Biomolecular Chemistry 16 (27), 5027-5035, 2018 | 17 | 2018 |
| Asymmetric synthesis of dihydroartemisinic acid through intramolecular Stetter reaction RK Rej, RK Acharyya, S Nanda Tetrahedron 72 (32), 4931-4937, 2016 | 17 | 2016 |
| Exploration of Ring Rearrangement Metathesis Reaction: A General and Flexible Approach for the Rapid Construction [5,n]-Fused Bicyclic Systems en Route to … RK Acharyya, RK Rej, S Nanda The Journal of organic chemistry 83 (4), 2087-2103, 2018 | 16 | 2018 |
| Asymmetric Synthesis of 1, 2-Dihydronaphthalene-1-ols via Copper-Catalyzed Intramolecular Reductive Cyclization RK Acharyya, S Kim, Y Park, JT Han, J Yun Organic Letters 22 (20), 7897-7902, 2020 | 13 | 2020 |
| Asymmetric total synthesis of cryptoconcatone I RK Acharyya, P Pal, S Chatterjee, S Nanda Organic & Biomolecular Chemistry 17 (14), 3552-3566, 2019 | 8 | 2019 |
| Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity Z Chen, B Hu, RK Rej, D Wu, RK Acharyya, M Wang, T Xu, J Lu, ... Journal of Medicinal Chemistry 66 (17), 12559-12585, 2023 | 7 | 2023 |
| Synthetic studies towards naturally occurring γ-(Z)/(E)-alkylidenebutenolides through bimetallic cascade cyclization and an adventitious photoisomerization method S Chatterjee, RK Acharyya, P Pal, S Nanda Organic & Biomolecular Chemistry 20 (12), 2473-2499, 2022 | 4 | 2022 |
| Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs RK Rej, SR Allu, J Roy, RK Acharyya, INC Kiran, Y Addepalli, ... Pharmaceuticals 17 (4), 494, 2024 | | 2024 |
| Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving complete tumor regression H Zhou, D Wu, L Bai, RK Acharyya, H Metwally, D McEachern, B Wen, ... Cancer Research 84 (6_Supplement), 4519-4519, 2024 | | 2024 |
| Potent and orally efficacious PROTAC degraders of estrogen receptor α (ERα) RK Rej, Z Chen, RK Acharyya, D Wu, B Hu, G Xu, R Nagilla, H Metwally, ... Cancer Research 84 (6_Supplement), 4510-4510, 2024 | | 2024 |
| Evaluation of a highly potent and selective STAT3 degrader as a new class of immunotherapy L Bai, H Zhou, J Zhou, D Wu, RK Acharyya, H Metwally, D McEachern, ... Cancer Research 84 (6_Supplement), 6057-6057, 2024 | | 2024 |
| Discovery of potent and highly efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression RK Acharyya, L Bai, H Zhao, D Wu, M Hoda, ME Donna, W Bo, D Sun, ... Cancer Research 84 (6_Supplement), 4509-4509, 2024 | | 2024 |
| Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression H Zhou, D Wu, L Bai, RK Acharyya, H Metwally, D McEachern, B Wen, ... Cancer Research 84 (6_Supplement), 3881-3881, 2024 | | 2024 |
| Cereblon Ligands and Uses Thereof S Wang, Z Chen, D Wu, YM Siu, R Rej, RK Acharyya, W Xiang, L Bai US Patent App. 18/220,959, 2024 | | 2024 |
| Cereblon Ligands and Uses Thereof S Wang, Z Chen, D Wu, RK Acharyya, W Xiang, R Rej, L Bai, X Zhang, ... US Patent App. 18/221,005, 2024 | | 2024 |
| Cereblon ligands and uses thereof R Rej, Z Chen, L Bai, RK Acharyya, D Wu, P Kirchhoff, Z Li | | 2024 |
| Indole derivatives as estrogen receptor degraders and their preparation Z Chen, M Wang, D Wu, G Xu, RK Acharyya, B Hu, J Lu, S Wang | | 2024 |
| Chroman derivatives as estrogen receptor degraders and their preparation G Xu, RK Acharyya, R Rej, Z Chen, B Hu, J Lu, S Wang | | 2024 |
| Indazole derivatives as estrogen receptor degraders Z Chen, R Rej, G Xu, D Wu, RK Acharyya, M Wang, B Hu, J Lu, S Wang | | 2024 |
